Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

Exclusion Criteria

• •History of any clinically significant cardiac, endocrine, gastrointestinal (GI), hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator
• •Clinically significant abnormal laboratory test values, as determined by the Investigator, at Screening or Day -1
• •History of, or positive test result at Screening for, human immunodeficiency virus (HIV)
• •Treatment with any prescription or over-the-counter oral medication (excluding acetaminophen) within 14 days prior to Day -1 and an unwillingness or inability to refrain from this treatment during study participation, unless specifically permitted elsewhere within this protocol.
• •Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrollment.